Sanders D S, Blessing K, Hassan G A, Bruton R, Marsden J R, Jankowski J
Department of Histopathology, University Hospital Birmingham Trust, Edgbaston, UK.
Mol Pathol. 1999 Jun;52(3):151-7. doi: 10.1136/mp.52.3.151.
Compelling evidence from cell culture studies implicates cadherins in the neoplastic progression of melanocytic tumours but few reports describe the expression of cadherins and the related transmembrane proteins, catenins, in a full range of benign and malignant excised melanocytic tumours.
Using immunohistochemistry and western blotting after tissue fractionation, the pattern of expression of cadherins/catenins was studied in a range of surgically excised melanocytic tumours, from dysplastic naevi to stage III cutaneous metastatic malignant melanoma.
Appropriate membranous expression of E-cadherins and P-cadherins is seen in dysplastic naevocytes with an epithelioid phenotype and is largely maintained with malignant transformation to radial growth phase melanoma and primary vertical growth phase malignant melanoma. Loss of membranous E-cadherin is seen in a small number of vertical growth phase melanomas only when metastasis has occurred. However, there is a concomitant dramatic loss of membranous P-cadherin expression in all melanomas at the same stage. A minority of metastatic melanomas show de novo membranous N-cadherin expression in comparison with dysplastic naevi and primary melanoma. Membranous expression of the desmosomal cadherin, desmoglein, was not seen in any tumour studied. Frequently, beta catenin is aberrantly produced in the cytoplasm of cells in dysplastic naevi and metastatic malignant melanoma, with an implied compromise to adhesive function. Furthermore, membranous gamma catenin expression was not seen in any of the 70 melanocytic tumours studied, implying obligatory transmembrane binding of cadherins to beta catenin for maintenance of adhesive function.
The most important alterations in membranous cadherin and catenin expression are seen late in the biological progression of melanocytic tumours at the stage of "in transit" or regional lymph node metastasis, with implications for tumour growth, invasion, and dissemination.
细胞培养研究的有力证据表明钙黏蛋白与黑素细胞肿瘤的肿瘤进展有关,但很少有报告描述钙黏蛋白及相关跨膜蛋白连环蛋白在一系列切除的良性和恶性黑素细胞肿瘤中的表达情况。
采用免疫组织化学和组织分级后的蛋白质印迹法,研究了一系列手术切除的黑素细胞肿瘤(从发育异常痣到III期皮肤转移性恶性黑色素瘤)中钙黏蛋白/连环蛋白的表达模式。
在具有上皮样表型的发育异常痣细胞中可见E-钙黏蛋白和P-钙黏蛋白的适当膜表达,并且在向放射状生长期黑色素瘤和原发性垂直生长期恶性黑色素瘤的恶性转化过程中基本保持。仅在发生转移时,少数垂直生长期黑色素瘤中可见膜性E-钙黏蛋白的缺失。然而,在同一阶段的所有黑色素瘤中,膜性P-钙黏蛋白表达同时出现显著缺失。与发育异常痣和原发性黑色素瘤相比,少数转移性黑色素瘤显示有新生的膜性N-钙黏蛋白表达。在所研究的任何肿瘤中均未见到桥粒钙黏蛋白桥粒芯糖蛋白的膜表达。在发育异常痣和转移性恶性黑色素瘤的细胞胞质中,β连环蛋白经常异常产生,这意味着黏附功能受到损害。此外,在所研究的70例黑素细胞肿瘤中均未见到膜性γ连环蛋白表达,这意味着钙黏蛋白与β连环蛋白的跨膜结合对于维持黏附功能是必需的。
膜性钙黏蛋白和连环蛋白表达的最重要改变见于黑素细胞肿瘤生物学进展的晚期,即“途中”转移或区域淋巴结转移阶段,这对肿瘤的生长、侵袭和播散具有重要意义。